About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Market Cap
$0.38B
Employees
9
Listed Since
May 2, 2014
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.aldeyra.comPhone
781-761-4904
Headquarters
131 HARTWELL AVENUE
LEXINGTON, MA 02421
CIK
0001341235